The phase 3 EMBRACA trial evaluated the efficacy and safety of talazoparib compared to standard treatment with a chemotherapeutic agent of the physician’s choice in patients with locally advanced or metastatic BC with germline BRCA1/2 mutation [73]. The gene discussed is BRCA1; the disease is breast cancer.